Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients
Background Tumor response characteristics using immune-related RECIST1.1 (irRECIST1.1) in advanced non-small-cell lung cancer (NSCLC) patients treated with nivolumab monotherapy in the clinical setting have not been previously described with a direct comparison with the assessments according to the...
שמור ב:
| Principais autores: | , , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BMJ Publishing Group
2016-12-01
|
| סדרה: | Journal for ImmunoTherapy of Cancer |
| גישה מקוונת: | https://jitc.bmj.com/content/4/1/84.full |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|